Clonal Haematopoiesis and Ageing Biology
Key Takeaways
- Clonal haematopoiesis occurs when descendants of one blood-forming stem or progenitor cell make up a detectable share of blood production. It becomes more common with age. [1] [2]
- Mutations in genes such as DNMT3A, TET2, and ASXL1 can give a clone a context-dependent competitive advantage, but mutation, clone size, and growth rate vary substantially. [2] [5]
- Clonal haematopoiesis is associated with higher risks of myeloid malignancy and cardiovascular disease, yet most people with a detected clone do not have a blood cancer. [1] [3] [7]
- It is both a marker of somatic evolution in an ageing tissue and, for some mutations, a possible contributor to inflammatory disease biology. [7] [8]
Blood is continuously renewed by haematopoietic stem and progenitor cells. Over a lifetime, these cells acquire somatic mutations, and some mutated cells leave unusually large populations of descendants. This uneven contribution to blood production is called clonal haematopoiesis. Population sequencing studies established that detectable clones are uncommon in younger adults and increasingly frequent at older ages. [1] [2]
Who This Is Useful For
This page is for readers who want to understand why ageing blood becomes more genetically mosaic, how clone selection differs from cancer, and why clonal haematopoiesis appears in research on inflammation and age-related disease. It also provides context for interpreting sequencing results without treating every detected clone as a diagnosis.
Clonal Haematopoiesis and CHIP Are Related, but Not Identical
Clonal haematopoiesis is a broad biological description. Clonal haematopoiesis of indeterminate potential, or CHIP, is a narrower category proposed for people with a somatic mutation associated with haematological malignancy, a clone meeting a specified detection threshold, and no diagnosed blood cancer or other defining haematological disorder. The commonly used variant allele fraction threshold of 2% was a practical convention, not a biological boundary between harmless and harmful clones. [3]
Terminology therefore depends on what is measured. Clones may carry point mutations, small insertions or deletions, or larger chromosomal changes, and increasingly sensitive sequencing can detect smaller clones. Reported prevalence is consequently shaped by participant age, genes examined, sequencing depth, and the threshold used to call a clone. [3] [9]
Why Clones Expand with Age
Mutation accumulation alone does not fully explain clonal expansion. A mutation must occur in a long-lived cell, persist through self-renewal, and confer an advantage under the conditions present in the marrow. Longitudinal data show that different driver genes produce different growth patterns: clones with some mutations expand steadily, whereas others remain stable or become prominent mainly later in life. [4] [5]
Whole-genome reconstruction of blood-cell lineages indicates that healthy adult blood production is highly polyclonal before later life, while a much smaller number of expanded clones can account for a large fraction of blood production in older people. Many expanded clones in these studies lacked a recognised blood-cancer driver, showing that current gene panels capture only part of age-related clonal selection. [6]
Genes, Cell Fitness, and Context
| Dimension | What Studies Commonly Observe | Interpretive Limit |
|---|---|---|
| Driver gene | DNMT3A, TET2, and ASXL1 are frequent, with additional mutations affecting signalling, splicing, and DNA-damage responses. [1] [2] | Mutations in different genes, and even different variants in one gene, need not have the same growth dynamics or consequences. [5] |
| Clone size | Variant allele fraction is often used as an approximate measure of the proportion of sampled blood cells carrying a mutation. [3] | It is assay-dependent and does not directly measure every stem cell or identify the full clonal architecture. [4] |
| Ageing environment | Inflammatory and other stresses can alter competition between mutant and non-mutant stem cells. [8] [10] | Evidence is gene- and context-specific; “inflammation” is not a single uniform selective pressure. [10] |
| External exposure | Some cancer therapies preferentially select pre-existing clones with mutations in DNA-damage-response genes. [11] | An exposure may select a clone rather than create every mutation detected after exposure. [11] |
Inflammation as Both Environment and Output
Age-associated inflammation can change the marrow environment in which stem cells compete. Human single-cell studies suggest that common mutant stem cells may respond differently from non-mutant cells to inflammatory and ageing-associated signals, potentially helping selected clones persist or expand. This relationship is not necessarily one-way: mature immune cells produced by a clone may also acquire altered inflammatory behaviour. [8] [10]
In mouse models, partial loss of Tet2 in blood-forming cells increases inflammatory signalling in descendant myeloid cells and accelerates atherosclerosis. These experiments support a causal route from a specific clone to vascular pathology, but they do not establish that every human clone, driver gene, or cardiovascular outcome operates through the same mechanism. [8]
Associations with Disease
Large human cohort studies associate detectable clonal haematopoiesis with a higher relative risk of later haematological malignancy. Absolute progression risk remains much lower than the relative-risk figure might imply, because blood cancers are uncommon and risk is heterogeneous across clone size, mutation pattern, and accompanying blood abnormalities. CHIP is therefore a risk state rather than an early cancer diagnosis in every carrier. [1] [2] [3]
Clonal haematopoiesis has also been associated with coronary heart disease and ischaemic stroke. A study combining human cohorts with mouse experiments found an approximately twofold association with coronary heart disease and showed accelerated atherosclerosis after experimental disruption of Tet2. The epidemiology establishes association, while the experimental work provides mutation-specific mechanistic support rather than proof that all observed human cardiovascular risk is caused by clonal haematopoiesis. [7] [8]
Evidence Quality and Interpretation
Confidence is strong that clonal expansions become more detectable with age, that clone dynamics vary by mutation, and that some clones precede myeloid malignancy. These conclusions are supported by large cross-sectional cohorts, repeated sampling, and lineage reconstruction from single-cell-derived colonies. [1] [2] [4] [6]
Greater uncertainty remains around how much a particular clone contributes to non-cancer disease in an individual. Human associations can be affected by shared causes, while mechanistic experiments often model one mutation in mice under controlled conditions. Gene identity, variant, clone size, cell lineage, co-mutations, exposure history, and the surrounding inflammatory environment may all modify the result. [7] [8] [10] [11]
What This Does Not Mean
- A detected clone is not equivalent to leukaemia or another blood cancer. [3]
- Age alone does not determine which mutation occurs or how quickly its clone grows. [4] [5]
- A 2% variant allele fraction is not a universal biological threshold separating safe from unsafe clones. [3]
- An association with cardiovascular disease does not show that every clone causes cardiovascular disease through the same pathway. [7] [8]
- Clonal haematopoiesis does not explain all immune ageing or all age-related decline in blood production. [6] [10]
Practical Interpretation Examples
- If a study reports more CHIP in an older group: check the age distribution, sequencing depth, genes tested, and minimum clone size before comparing prevalence with another study. [3] [9]
- If a clone is present at two time points: the change in variant allele fraction and the driver gene are more informative about dynamics than presence alone. [4] [5]
- If a mutation is found after chemotherapy: consider selection of a pre-existing resistant clone as well as new mutation formation. [11]
- If animal work links one mutation to inflammation: treat it as evidence for a defined mechanism, not as a universal account of all human clonal haematopoiesis. [8]
Summary
Clonal haematopoiesis makes somatic evolution visible in an accessible human tissue. With age, blood production can shift from broad polyclonality toward greater contribution by selected stem-cell clones. The process links mutation, cellular competition, marrow environment, and inflammatory output, but its meaning depends on the particular mutation, clone, assay, and person. It is best understood as a heterogeneous feature of ageing biology that can mark risk and, in defined settings, participate in disease mechanisms. [4] [6] [7] [8]
References
- Jaiswal, S., et al. (2014). "Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes." New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1408617
- Genovese, G., et al. (2014). "Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence." New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1409405
- Steensma, D. P., et al. (2015). "Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes." Blood. https://pubmed.ncbi.nlm.nih.gov/25931582/
- Fabre, M. A., et al. (2022). "The longitudinal dynamics and natural history of clonal haematopoiesis." Nature. https://www.nature.com/articles/s41586-022-04785-z
- Robertson, N. A., et al. (2022). "Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects." Nature Medicine. https://www.nature.com/articles/s41591-022-01883-3
- Mitchell, E., et al. (2022). "Clonal dynamics of haematopoiesis across the human lifespan." Nature. https://www.nature.com/articles/s41586-022-04786-y
- Jaiswal, S., et al. (2017). "Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease." New England Journal of Medicine. https://www.nejm.org/doi/abs/10.1056/NEJMoa1701719
- Fuster, J. J., et al. (2017). "Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice." Science. https://pubmed.ncbi.nlm.nih.gov/28104796/
- Bick, A. G., et al. (2020). "Inherited causes of clonal haematopoiesis in 97,691 whole genomes." Nature. https://www.nature.com/articles/s41586-020-2819-2
- Jakobsen, N. A., et al. (2024). "Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging." Cell Stem Cell. https://pubmed.ncbi.nlm.nih.gov/38917807/
- Bolton, K. L., et al. (2020). "Cancer therapy shapes the fitness landscape of clonal hematopoiesis." Nature Genetics. https://www.nature.com/articles/s41588-020-00710-0
This content is provided for educational purposes only and does not constitute medical advice.